Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients

被引:47
作者
Gurbel, Paul A. [1 ]
Bliden, Kevin P. [1 ]
Etherington, Amena [1 ]
Tantry, Udaya S. [1 ]
机构
[1] Sinai Ctr Thrombos Res, Baltimore, MD 21215 USA
关键词
platelet; clopidogrel; non-responsiveness; P2Y12; receptor; maximum aggregation; late aggregation;
D O I
10.1016/j.thromres.2007.02.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Controversy surrounds the optimal platelet aggregation measurement to assess clopidogrel non-responsiveness. The P2Y12 reactivity ratio (PRR) determined by vasoditator-stimulated phosphoprotein phosphorylation levels has been used to indicate the extent of P2Y12 blockade. Objectives: We sought to compare the prevalence of non-responsiveness measured by maximum (MA) and 6 min aggregation (FA) and correlate these measurements with PRR in patients with non-responsiveness. Methods: MA and FA were measured in stented patients (n = 100) before and after clopidogrel treatment. The PRR was determined in 22 non-responsive patients. Responsiveness was defined as pre-treatment minus post-treatment aggregation; and non-responsiveness was defined as < 10% change in platelet aggregation. Results: Responsiveness was greater as determined by FA, p=0.006 (5 PM ADP) and p=0.003 (20 mu M ADP)). There was a strong correlation between MA and FA stimulated by 5 mu M (r=0.84, p < 0.0001) and 20 mu M ADP (r=0.90, p < 0.001). The prevalence of non-responsiveness rose with agonist concentration but did not differ significantly between methods: 5 mu M ADP [22% (MA) vs. 17% (FA), p = 0. 186] and 20 mu M ADP [33% (MA) vs. 29% (FA), p=0.270]. PRR correlated with both MA (r=0.66, p < 0.001) and FA (r= 0.74, p < 0.001) in non-responsive patients indicating incomplete receptor blockade. Conclusion: Clopidogrel responsiveness is higher when measured by FA as compared to
引用
收藏
页码:107 / 115
页数:9
相关论文
共 28 条
[1]   Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis - A case-control study [J].
Ajzenberg, N ;
Aubry, P ;
Huisse, MG ;
Cachier, A ;
El Amara, W ;
Feldman, LJ ;
Himbert, D ;
Baruch, D ;
Guillin, MC ;
Steg, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (11) :1753-1756
[2]   Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [J].
Aleil, B ;
Ravanat, C ;
Cazenave, JP ;
Rochoux, G ;
Heitz, A ;
Gachet, C .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :85-92
[3]   Aspirin and clopidogrel - Efficacy, safety, and the issue of drug resistance [J].
Cattaneo, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (11) :1980-1987
[4]   High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome [J].
Cuisset, T ;
Frere, C ;
Quilici, J ;
Barbou, F ;
Morange, PE ;
Hovasse, T ;
Bonnet, JL ;
Alessi, MC .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (03) :542-549
[5]   Specific impairment of human platelet P2YAC ADP receptor-mediated signalling by the antiplatelet drug clopidogrel [J].
Geiger, J ;
Brich, J ;
Hönig-Liedl, P ;
Eigenthaler, M ;
Schanzenbächer, P ;
Herbert, JM ;
Walter, U .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (08) :2007-2011
[6]   Monitoring of clopidogrel action: Comparison of methods [J].
Geiger, J ;
Teichmann, L ;
Grossmann, R ;
Aktas, B ;
Steigerwald, U ;
Walter, U ;
Schinzel, R .
CLINICAL CHEMISTRY, 2005, 51 (06) :957-965
[7]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[8]   Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention:: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial [J].
Greenbaum, AB ;
Grines, CL ;
Bittl, JA ;
Becker, RC ;
Kereiakes, DJ ;
Gilchrist, IC ;
Clegg, J ;
Stankowski, JE ;
Grogan, DR ;
Harrington, RA ;
Emanuelsson, H ;
Weaver, WD .
AMERICAN HEART JOURNAL, 2006, 151 (03) :689.e1-689.e10
[9]   A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease [J].
Gum, PA ;
Kottke-Marchant, K ;
Welsh, PA ;
White, J ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) :961-965
[10]   The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting [J].
Gurbel, PA ;
Bliden, KP ;
Hayes, KM ;
Yoho, JA ;
Herzog, WR ;
Tantry, US .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (09) :1392-1396